Drug Kinetics – Multimedia

Discover an automated solution for the consolidation and ranking of your metabolite structures. Explore a workflow that utilizes both EAD and CID data for the most confident characterization and streamlined data acquisition.

Conventional bioassays often require labeled detection reagents to provide a measurable readout. However, modifications to molecular structure and/or function can skew results, and non-specific binding of the labels themselves can lead to an unwanted background signal.

Understanding the effects of in vitro drug metabolism is a key aspect of drug discovery and development. However, researchers must be able to make confident decisions quickly and easily.

Early ADME studies are used to determine if a drug candidate is prone to metabolic breakdown or oxidation/conjugation.

Conducting in vitro ADME drug-drug interaction (DDI) studies early on in the drug development process is more than simply a box checking exercise to satisfy regulatory requirements. The information provided by these studies provides a deeper understanding of the molecule to the drug developer helping to inform go or no-go decisions early on.

Hear expert Dr. Brian Ogilvie discuss the differences between current in vitro drug-drug interaction guidance from the relevant US FDA, EMA and PMDA guidance documents, and how to plan drug development strategies to meet the ICH M12 guideline.

Proteolysis targeting chimera (PROTAC) degraders are used to treat drug-resistant targets via targeted protein degradation.

This presentation was one of the keynote presentations from XenoTech's XenoTalks™ Seminar Series on the importance of ADME and Drug-Drug Interactions in drug development.

This informative ADME 101 discusses In Vitro to In Vivo Extrapolation (IVIVE) and how a model-based approach following routine perpetrator potential studies (i.e. CYP inhibition, CYP induction, and transporter inhibition) assessing clinical potential may eliminate the need of conducting clinical studies.

In early-stage pharmaceutical research, knowledge of a compound’s metabolism can assist in the identification of structural liabilities that can contribute to non-optimal pharmacokinetics, potentially toxic breakdown products or the potential for drug-drug interactions.